CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development.

Autor: Melese ES; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada., Franks E; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Cederberg RA; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Harbourne BT; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Shi R; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Wadsworth BJ; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Collier JL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Halvorsen EC; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Johnson F; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Luu J; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Oh MH; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Lam V; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada., Krystal G; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada., Hoover SB; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Raffeld M; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Simpson RM; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Unni AM; Weill Cornell Medicine, New York, NY, USA., Lam WL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Lam S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Abraham N; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.; Department of Zoology, University of British Columbia, Vancouver, BC, Canada., Bennewith KL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Lockwood WW; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Dec 30; Vol. 11 (1), pp. 2010905. Date of Electronic Publication: 2021 Dec 30 (Print Publication: 2022).

CXCL5 impedes CD8⁺ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.

Autor: Sun, Dantong¹ (AUTHOR), Tan, Lipin² (AUTHOR), Chen, Yongbing¹ (AUTHOR), Yuan, Qiang³ (AUTHOR), Jiang, Kanqiu¹ (AUTHOR), Liu, Yangyang⁴ (AUTHOR), Xue, Yuhang⁵ (AUTHOR), Zhang, Jinzhi¹ (AUTHOR), Cao, Xianbao¹ (AUTHOR), Xu, Minzhao¹ (AUTHOR), Luo, Yang¹ (AUTHOR), Xu, Zhonghua¹ (AUTHOR), Xu, Zhonghen¹ (AUTHOR), Xu, Weihua¹ (AUTHOR), Shen, Mingjing¹ (AUTHOR) shenmingjing0707@126.com

Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 7/22/2024, Vol. 43 Issue 1, p1-15. 15p.

Exercise accelerates recruitment of CD8⁺ T cell to promotes anti-tumor immunity in lung cancer via epinephrine.

Autor: Miao, Sai-Nan¹ (AUTHOR), Chai, Meng-Qi¹ (AUTHOR), Liu, Xiang-Yu¹ (AUTHOR), Wei, Cheng-Yu¹ (AUTHOR), Zhang, Cun-Cun¹ (AUTHOR), Sun, Ning-Ning¹ (AUTHOR), Fei, Qing-Ze¹ (AUTHOR), Peng, Lin-Lin¹ (AUTHOR), Qiu, Huan¹ (AUTHOR) huanqiu@ahmu.edu.cn

Publikováno v: BMC Cancer. 4/15/2024, Vol. 24 Issue 1, p1-16. 16p.

Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.

Autor: Qian, Baolin^1,2 (AUTHOR), Liu, Qi³ (AUTHOR), Wang, Chaoqun^1,2 (AUTHOR), Lu, Shounan^1,2 (AUTHOR), Ke, Shanjia^1,2 (AUTHOR), Yin, Bing^1,2 (AUTHOR), Li, Xinglong^1,2 (AUTHOR), Yu, Hongjun^1,2 (AUTHOR), Wu, Yaohua⁴ (AUTHOR) wuyaohua07@163.com, Ma, Yong^1,2 (AUTHOR) mayong@ems.hrbmu.edu.cn

Publikováno v: Scientific Reports. 9/23/2023, Vol. 13 Issue 1, p1-15. 15p.

Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer.

Autor: Hu, Yue¹ (AUTHOR), Li, Shixun¹ (AUTHOR), Xiao, He¹ (AUTHOR), Xiong, Yanli¹ (AUTHOR), Lu, Xianfeng¹ (AUTHOR), Yang, Xiao¹ (AUTHOR), Luo, Wei¹ (AUTHOR), Luo, Jiamin¹ (AUTHOR), Zhang, Shiheng¹ (AUTHOR), Cheng, Yi¹ (AUTHOR), Zhang, Lei¹ (AUTHOR), Dai, Xiaoyan¹ (AUTHOR), Yang, Yuxin¹ (AUTHOR), Wang, Dong¹ (AUTHOR), Li, Mengxia¹ (AUTHOR) mengxia.li@outlook.com

Publikováno v: Cancer Medicine. Jun2023, Vol. 12 Issue 11, p12234-12252. 19p.